Dronedarone and amiodarone are structurally similar antiarrhythmic drugs. Dronedarone worsens cardiac adverse effects with unknown causes while amiodarone has no cardiac adversity. Dronedarone induces preclinical mitochondrial toxicity in rat liver and exhibits clinical hepatotoxicity. Here, we further investigated the relative potential of the antiarrhythmic drugs in causing mitochondrial injury in cardiomyocytes. Differentiated rat H9c2 cardiomyocytes were treated with dronedarone, amiodarone, and their respective metabolites namely N-desbutyldronedarone (NDBD) and N-desethylamiodarone (NDEA). Intracellular ATP content, mitochondrial membrane potential (Dw m ), and inhibition of carnitine palmitoyltransferase I (CPT1) activity and arachidonic acid (AA) metabolism were measured in H9c2 cells. Inhibition of electron transport chain (ETC) activities and uncoupling of ETC were further studied in isolated rat heart mitochondria. Dronedarone, amiodarone, NDBD and NDEA decreased intracellular ATP content significantly (IC 50 ¼ 0.49, 1.84, 1.07, and 0.63 mM, respectively) and dissipated Dw m potently (IC 50 ¼ 0.5, 2.94, 12.8, and 7.38 mM, respectively). Dronedarone, NDBD, and NDEA weakly inhibited CPT1 activity while amiodarone (IC 50 > 100 mM) yielded negligible inhibition. Only dronedarone inhibited AA metabolism to its regioisomeric epoxyeicosatrienoic acids (EETs) consistently and potently. NADH-supplemented ETC activity was inhibited by dronedarone, amiodarone, NDBD and NDEA (IC 50 ¼ 3. 07, 5.24, 11.94, and 16.16 mM, respectively). Cytotoxicity, ATP decrease and Dw m disruption were ameliorated via exogenous pretreatment of H9c2 cells with 11, 12-EET and 14, 15-EET. Our study confirmed that dronedarone causes mitochondrial injury in cardiomyocytes by perturbing Dw m , inhibiting mitochondrial complex I, uncoupling ETC and dysregulating AA-EET metabolism. We postulate that cardiac mitochondrial injury is one potential contributing factor to dronedarone-induced cardiac failure exacerbation.
, and ischemia-reperfusion injury (Schwarz et al., 2014) . Mitochondrial dysfunction is also implicated in heart failure worsening. Sustained stimulation of reninangiotensin-aldosterone system dysregulates glucose metabolism and fatty acid b-oxidation, suppresses activities of the mitochondrial electron transport chain (ETC) complexes, uncouples ETC, impairs mitochondrial biogenesis, reduces stress signaling and antioxidant defenses (reviewed in Abel and Doenst, 2011; Rosca and Hoppel, 2013) .
Dronedarone ( Figure 1A ) and amiodarone ( Figure 1B ) are antiarrhythmic drugs prescribed for the treatment of atrial fibrillation (AF) and undergo extensive hepatic metabolism by Cytochrome P450 (CYP)3A4/5 to their main, antiarrhythmic Ndealkyl metabolites namely N-desbutyldronedarone (NDBD) ( Figure 1C ) and N-desethylamiodarone (NDEA) ( Figure 1D ) (Oyetayo et al., 2010; Trivier et al., 1993) . Both amiodarone and dronedarone cause mitochondrial damage in hepatocytes manifesting mild to severe hepatitis or liver cirrhosis in patients (Jahn et al., 2013; Spaniol et al., 2001; Waldhauser et al., 2006) . Although amiodarone causes significant respiratory chain dysfunction and oxidative stress (Serviddio et al., 2011) , dronedarone intercedes its hepatotoxicity primarily via inhibition of carnitine palmitoyltransferase I (CPT1) and thereby mitochondrial fatty acid b-oxidation instead of the mitochondrial ETC (Felser et al., 2013 (Felser et al., , 2014 .
Clinically, dronedarone increases mortality in patients with permanent AF (Connolly et al., 2011) or New York Heart Association classes III and IV heart failure (Køber et al., 2008) while amiodarone does not yield clinically significant cardiac adverse effects. The causes for the cardiac toxicological endpoint of dronedarone are currently unknown. We postulate that modulation of mitochondrial function may contribute to dronedarone-induced exacerbation of cardiac failure.
Arachidonic acid (AA) is metabolized by cardiac CYP450 enzymes namely CYP2C8, CYP2C9, and CYP2J2 to 4 regioisomeric, cardioprotective epoxyeicosatrienoic acids (EETs) (Figure 2 ) (Rifkind et al., 1995; Wu et al., 1996) . EETs are known to protect the heart against toxic insults mainly by activation of mitochondrial (mitoK ATP ) and sarcolemmal ATP-sensitive potassium channels (Gross et al., 2007; Katragadda et al., 2009; Seubert, 2004) . Activation of mitoK ATP reduces intracellular Ca 2þ overload and increases in K þ uptake, moderates the release of stress signals, lowers Dw m dissipation, preserves cellular nucleotides and enhances oxidative phosphorylation (Garlid et al., 2003) . Conversely, perturbation in EET levels leads to the initiation and sustenance of cardiac hypertrophy, a precedent to heart failure (Alsaad et al., 2012; Althurwi et al., 2015) . We have previously reported that dronedarone, amiodarone, NDBD and NDEA are potent reversible inhibitors and mechanismbased inactivators of CYP2J2 (Karkhanis et al., 2016) . Subsequently, static sequential metabolism model predicted that dronedarone and NDBD yield a relatively greater decrease in cardiac EET levels compared with amiodarone and NDEA (Karkhanis et al., 2017) . Owing to the importance of mitochondria in energy homeostasis, its implication in heart failure worsening and the contrasting mitotoxic mechanisms of dronedarone and amiodarone in hepatocytes, we investigated the mechanisms of mitotoxicity by dronedarone, amiodarone, NDBD, and NDEA in H9c2, a rat ventricular cardiomyocyte cell line. Additionally, we investigated the effects of exogenously administered EETs in mitigating toxicity induced by dronedarone, amiodarone, NDBD and NDEA. Finally, we determined whether dronedarone, amiodarone, NDBD and NDEA inhibit the metabolism of AA to EETs in H9c2 cells. Taken together, our study illuminates the currently arcane role of mitochondrial toxicity in dronedaroneinduced cardiac adverse effects.
MATERIALS AND METHODS
Reagents. High-performance liquid chromatography-grade acetonitrile (ACN) was purchased from Tedia Company Inc. (Fairfield, Ohio) . Dronedarone hydrochloride, amiodarone hydrochloride, carbonyl cyanide 3-chlorophenylhydrazone (CCCP), danazol, sulfaphenazole were purchased from Sigma-Aldrich (St Louis, Missouri). NDBD hydrochloride was purchased from Alsachim Inc. (lllkirch, France) . N-(methylsulfonyl)-2-(2-propynyloxy)-benzenehexanamide (MS-PPOH), NDEA hydrochloride, AA, 14, 15-EET, 11, 12-EET, 8, 9-EET, 5, 6-EET, etomoxir were purchased from Cayman Chemical (Ann Arbor, Michigan). Water was obtained using a Milli-Q water purification system (Millipore, Billerica, Massachusetts). All other reagents were of analytical grade and purchased from Sigma-Aldrich (St Louis, Missouri) unless otherwise mentioned.
H9c2 cell culture. H9c2 cell line was purchased from American Tissue Type Collection (Manassas, Virginia). The cells were cultured in low-glucose DMEM growth media (Cat No: 31600, Thermofisher, Waltham, Massachusetts) supplemented with 1.5 g/l sodium bicarbonate, 25 mM 4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid (HEPES), 10% fetal bovine serum (FBS) (GE Healthcare, Singapore), 100 U/ml penicillin, 100 mg/ml streptomycin, and 250 ng/ml amphotericin B in 75-cm 2 tissueculture flasks at 37 C in a humidified atmosphere of 5% CO 2 .
Cells were fed every 2-3 days and sub-cultured once 70%-80% confluency was achieved to prevent the loss of differentiation potential. For differentiation, H9c2 cells were seeded at a density of 100 000 cells/well in 12-well plates. The cells were maintained for 1 day in low-glucose high-serum growth media to allow for cell attachment. Subsequently, cells were differentiated using 1 mM All-trans retinoic acid (ATRA) as described previously in Branco et al. (2011) and M enard et al. (1999) .
Total RNA isolation and relative gene expression. Total RNA was isolated from differentiated H9c2 cells and reverse transcribed to complimentary DNA. Complimentary DNA template was amplified as described in the Supplementary Material. The gene expression of cardiac markers namely cardiac troponin t (tnnt2); cyp2j3, rat isoform of CYP2J2; ephx2, soluble epoxide hydrolase (sEH); cpt1a (liver), and cpt1b (heart/muscle) isoforms of cpt1 was measured using primers listed in Supplementary Table 1 .
Cell viability and ATP depletion. H9c2 cells were seeded in a white chimney plate and differentiated. The media was changed to DMEM with 10 mM galactose, 2 mM glutamine (6 mM final), 5 mM HEPES, 1 mM sodium pyruvate, 100 U/ml penicillin, 100 mg/mL streptomycin, 0.25 mg/ml amphotericin B, 1% FBS, 1Â insulin-transferrin-selenium and 1 mM ATRA for 48 h to overcome the Crabtree effect (Marroquin et al., 2007) . Cells were treated with dronedarone (2 mM), amiodarone (5 mM), NDBD (5 mM), and NDEA (5 mM) at different time points (0-6 h). Rotenone (10 mM) and malonate (100 mM) were used as positive control inhibitors against ETC complexes I and II, respectively. The cytotoxicity and intracellular ATP content were measured concurrently using Mitochondrial ToxGlo kit (Promega, Madison, Wiscosin) using manufacturer's protocol. Mitochondrial ToxGlo assay measures the cell viability using fluorogenic peptide bis-alanine-alanine-phenylalanine-R110 (bis-AAF-R110), which reacts with the dead-cell protease activity. ATP decrease is quantified using optimized formulation of luciferin, ATPase inhibitors and thermostable Ultra-Glo luciferase (Kamalian et al., 2015) .
Mitochondrial membrane potential (Dwm). Dissipation of Dw m by each test compound was measured using mitochondrial permeable dye, tetramethylrhodamine methyl ester perchlorate (TMRM) (Thermofisher, Waltham, Massachusetts). H9c2 cells were seeded at a density of 20 000 cells per well in a 96-well plate. The cells were treated with either dronedarone, amiodarone, NDBD or NDEA (0-10 mM) for 6 h, or CCCP for 1 h in serumfree low-glucose medium. CCCP, a known protonophore was used as a positive control. The media was discarded and the cells washed with 1Â PBS twice. TMRM dye (200 nM) was dissolved in serum free media and the plate was incubated for 30 min at 37 C. The media was aspirated, the cells were washed with PBS. In total 100 ml of methanol was added to the wells and the fluorescence was measured at 557 nm excitation and 570 nm emission wavelengths. TMRM concentration and the incubation time were optimized as described previously (Perry et al., 2011) .
Oxygen consumption in isolated rat heart mitochondria. The husbandry of the healthy male Wistar Han rats, the protocol for isolation of mitochondria from the rat heart and the evaluation of the purity by citrate synthase assay is described in the Supplementary Figure 1 . The activity of specific mitochondrial ETC was assessed using the Clarke-type oxygen electrode Digital Model 10 (Rank Brothers, Cambridge, UK) accompanied by Picolog software v5.20.9 (Pico Technology, Cambridgeshire, UK). Isolated mitochondria were freeze-thawed once before each experiment. Isolated mitochondria (1 mg/ml) were suspended in sucrose-Tris-EGTA (STE) buffer composed of 280 mM sucrose, 10 mM Tris-HCl, 1 mM EGTA, pH 7.4, and transferred to a precalibrated oxygen chambers at 37 C. Respiratory substrates NADH (1 mM) and succinate (4 mM) driven ETC activity was assessed in separate analyses. Rotenone (0.5 mM) and malonic acid (0.5 mM) were used as positive control inhibitors against complex I and II respectively. Dronedarone, amiodarone, NDBD, or NDEA were added to the incubation chamber at increasing concentrations (1-100 mM) using a Hamilton syringe. Percentage saturation was measured and extent of inhibition of the complexes was determined. The oxygen concentration level in a typical respiration buffer is approximately 230 nmol/ml (Mitsuda et al., 1962) . Hence 100% saturation was equated to 230 nmol/ml of dissolved oxygen for computation purpose. The extent of inhibition was reported as IC 50 values.
Mitochondrial ETC uncoupling. Freshly isolated mitochondria (1 mg/ml) were suspended in STE buffer with 5 mM potassium phosphate buffer and 5 mM MgCl 2 , pH 7.4 and transferred to a precalibrated oxygen chambers at 37 C. The mitochondria were treated with succinate (4 mM), ADP (100 mM), and rotenone (0.5 mM) followed by oligomycin A (0.5 mM). Dronedarone, amiodarone, NDBD or NDEA were added in increasing concentrations (0-50 mM) and CCCP (0.1 mM) was used as a positive control.
Percentage saturation was measured and the increase oxygen consumption due to the drugs post oligomycin A addition was calculated.
Inhibition of CPT1 activity in H9c2 cells. The isolation of mitochondria from H9c2 cells and the purity assessment by citrate synthase assay are described in Supplementary Figure 1 . The CPT1 inhibition method was adopted from (He et al., 2012) with some modifications. Mitochondrial suspension (6 mg) was mixed with assay buffer (final concentration of 117 mM Tris-buffered saline, 0.28 mM GSH, 4.4 mM MgCl 2 , 16.7 mM KCl, 5 mM KCN, 0.1% BSA, pH 7.4) with 25 mM palmitoyl-CoA in a 96-well plate. Each of the drugs and metabolites, and etomoxir were added to the incubation mixture at the intended concentrations and prewarmed for 5 min at 37 C. The reaction was initiated using 25 mM carnitine and incubated for 20 min at 37 C. The final volume of the reaction mixture was 50 ml. The reaction was quenched using 50 ml ice-cold ACN with ketoconazole as internal standard (2 mM). The samples were centrifuged at 3226 g at 4 C for 45 min. The supernatants were analyzed for palmitoylcarnitine and ketoconazole using LC-MS/MS.
Inhibition of CPT1 activity in isolated rat heart mitochondria. CPT1 activity assay was performed as described using isolated rat heart mitochondria (20 mg). The assay was carried out as described previously using H9c2 cells.
Detection of palmitoylcarnitine using LC-MS/MS. The LC-MS/MS system consisted of Agilent 1290 Infinity ultra-high pressure liquid chromatography system (Agilent Technologies Inc., Santa Clara, California) in tandem with AB SCIEX QTRAP 3500 tandem mass spectrometry (MS/MS) system (AB SCIEX, Framingham, MA). The LC-MS/MS system was controlled by Analyst 1.4.2 software (Applied Biosystems) which was used for chromatographic peak integration. The ACQUITY UPLC BEH C 18 column, 1.7 mM, 2.1 Â 50 mm (Waters, Milford, MA) was used for chromatographic separation. The mobile phase was 50 mM ammonium formate in water (solvent A) and 50 mM ammonium formate dissolved in 80% ACN/20% water (solvent B). The mobile phase was delivered at 0.8 ml/min while sample injection volume was 2 ml. The chromatographic separation was achieved using the following gradient method: linear gradient 70%-100% B (0-1 min), isocratic at 100% B (1.01-2 min), gradient from 100% to 70% B (2.01-2.50 min). The column temperature was 45 C and samples were maintained at 4 C. The MS/MS analysis was performed using positive ionization mode. The multiple reaction monitoring (MRM) transitions were m/z 978-471 for myristoyl-CoA, 400-85 for palmitoyl-carnitine, and 531-489 for ketoconazole. The MS source conditions were: curtain gas, 25 psi; collision gas, 9 psi; ionspray voltage, 3000 V; temperature, 600 C; ion source gas 1, 30 psi; and ion source gas 2, 60 psi. The compound-dependent MS parameters are summarized in Table 1 .
Metabolism of AA in H9c2 cells. The Michaelis-Menten kinetics of AA epoxygenation in differentiated H9c2 cells was determined as described in the Supplementary Material.
Inhibition of AA metabolism in H9c2 cells. Differentiated H9c2 cells were enriched with AA (90 mM) and treated with dronedarone (1 mM), amiodarone (1 mM), NDBD (1 mM), NDEA (1 mM), danazol (10 mM, CYP2J3 inhibitor), sulfaphenazole (10 mM, nonselective CYP2C inhibitor; El-Sherbeni and El-Kadi, 2014; Kobayashi et al., 2003) , and MS-PPOH (50 mM, pan-epoxygenase inhibitor; Wang et al., 1998) in serum-free low glucose medium supplemented with 1 mM ATRA. The cells were incubated for 2 h at 37 C in a humidified atmosphere of 5% CO, isolated and processed as described. The AA metabolites namely 5, 6-EET, 8, 9-EET, 11, 12-EET, and 14, 15-EET and internal standard 4-hydroxybenzophenone (4-HBP) were measured using LC-MS/MS.
Mitigation of cytotoxicity, ATP depletion and Dwm dissipation by 11, 12-EET and 14, 15-EET. Differentiated H9c2 cells were pretreated with 11, 12-EET and 14, 15-EET at varying concentrations (0-1 mM) for 2 h in serum-free galactose media. The media was aspirated and the cells were treated with dronedarone (2 mM), amiodarone (5 mM), NDBD (5 mM), NDEA (5 mM), and the cytotoxicity and intracellular ATP were measured. In a separate experiment, differentiated H9c2 cells were pretreated with 11, 12-EET and 14, 15-EET followed by dronedarone (2 mM), amiodarone (5 mM), NDBD (10 mM), NDEA (10 mM) in low-glucose media. The dissipation of Dw m using TMRM dye was measured as described earlier.
Reduction of Dwm protective effects of EETs by 5-hydroxydecanoate. Differentiated H9c2 cells were pretreated with either EET (0.1 mM), without EET (0 mM) or where EETs are co-incubated with 5-hydroxydecanoate (5-HD) (100 or 500 mM) for 2 h. 5-HD is a potent selective inhibitor of mitoK ATP channels (Auchampach et al., 1992) . The dissipation of Dw m was measured using TMRM dye as described earlier.
Data analysis. Data are given as the mean 6 SEM of at least 3 independent experiments. Experiments using H9c2 cells were performed across 3 passages unless mentioned. Statistical analyses were performed using GraphPad Prism 6 (La Jolla, California). Two-way analysis of variance (ANOVA) was used for comparisons of more than 2 groups, followed by Tukey's or Bonferroni's post hoc test procedure. p-values < .05 (*) were considered significant.
RESULTS

Differentiation of H9c2 Cells
H9c2 cells were differentiated using low glucose media supplemented with ATRA and 1% FBS. Significant expression of cardiac tnnt2 was observed at the end of 5 days (Supplementary Figure 2) .
Time and Concentration Dependent Cytotoxicity and ATP Depletion
After exposure of H9c2 cells to dronedarone, amiodarone, NDBD, and NDEA, we found a time-dependent decrease in the intracellular ATP levels (dashed line) while minimal increase in dead-cell protease activity indicative of cell death (solid line) at the same concentration of the drug (Figs. 3A-D) . All 4 test compounds caused 50% decrease in the intracellular ATP levels at 4 h while significant increase in cytotoxicity was observed only after 6 h. Rotenone ( Figure 3E ) and malonate ( Figure 3F ) depleted ATP with discordant changes in the cytotoxicity indicative of mitochondrial toxicity. (Figs. 4A-D) . CCCP, a known protonophore yielded IC 50 value of 0.027 mM ( Figure 4E ).
Measurement of Oxygen Consumption in Isolated Rat
Heart Mitochondria When the decrease in oxygen consumption rate (OCR) was plotted against logarithmic inhibitor concentrations, our results showed that dronedarone, amiodarone, NDBD and NDEA yielded concentration-dependent decrease in NADHsupplemented (Figs. 5A-D) and succinate-dependent ETC activities (Figs. 5E-H) . In terms of potency, dronedarone and amiodarone were marginally more potent than NDBD and NDEA for both NADH-and succinate-supplemented ETC inhibition (Table 2) . Dronedarone (4-fold), amiodarone (2-fold), NDBD (2-fold), and NDEA (1.6-fold) are more potent in inhibiting NADH-than succinate-dependent activity, underpinning their preferential inhibition of mitochondrial complex I ( Table 2) .
Measurement of ETC Uncoupling in Isolated Rat Heart Mitochondria
In our experiments, the decrease in oxygen level upon the succinate, ADP and rotenone showed functional well-coupled ETC bringing about OXPHOS. Oligomycin A addition led to inhibition of ATP synthase and decrease in the OXPHOS. Increase in oxygen consumption (posttest drug addition) in the presence of oligomycin indicated uncoupling of ETC from ATP synthase by the test drug. We found that the dronedarone and amiodarone caused significant uncoupling of ETC and respiratory leak at 0.1, 1, and 10 mM while NDBD and NDEA exhibited similar effects at 0.1 and 1 mM (Figure 6 ).
Inhibition of CPT1 Activity in H9c2 Cells
We first examined the expression of cpt1a and cpt1b genes in H9c2 cells and found that only cpt1a isoform was expressed (Supplementary Figure 2) . Next, CPT1 activity was measured in isolated H9c2 mitochondria using palmitoyl-CoA and carnitine as co-substrates. Our results revealed that dronedarone (IC 50 ¼ 40 mM) ( Figure 7A ), NDBD (IC 50 ¼ 10 mM) ( Figure 7B ), and NDEA (IC 50 ¼ 20 mM) ( Figure 7B ) inhibit CPT1 activity in H9c2 cells. Conversely, amiodarone did not inhibit CPT1 activity even at 100 mM ( Figure 7A ). As a positive control, etomoxir exhibited potent inhibition of CPT1 activity (IC 50 ¼ 50 nM) ( Figure 7A ).
Inhibition of CPT1 Activity in Isolated Rat Heart Mitochondria
Acute inhibition of CPT1 activity due to test drugs was also tested in isolated mitochondria. The concentrations for dronedarone (40 mM), amiodarone (100 mM), NDBD (20 mM), and NDEA (10 mM) were chosen based on the H9c2 data. Dronedarone and amiodarone were relatively less potent in inhibiting CPT1 activity in freshly isolated rat heart mitochondria compared with NDBD and NDEA since the metabolites exhibited similar extent of inhibition (approximately 40%) albeit at lower concentration levels (Supplementary Figure 3) . Etomoxir (50 nM) inhibited CPT1 activity to the same extent as the test drugs and metabolites and acted as a positive control.
Metabolism of AA in H9c2 Cells
We first found that H9c2 cells express cyp2j3 and ephx2 genes (Supplementary Figure 2) . Next, we determined that basal, intracellular levels of EETs are detectable but not quantifiable in H9c2 cells (Supplementary Figure 4A) . Subsequently, we enriched the H9c2 cells with AA and determined the MichaelisMenten parameters of AA metabolism (Supplementary Figure  4B) . The rate of formation of EETs (V max ) was highest for 14, 15-EET and lowest for 8, 9-EET (Supplementary Table 2 ).
Inhibition of AA Metabolism in H9c2 Cells
The inhibition of AA metabolism in H9c2 cells by dronedarone, amiodarone, NDBD and NDEA was investigated. Dronedarone (1 mM) inhibits the formation of all 4 regioisomeric EETs in H9c2 cells consistently (Figure 8) . Conversely, amiodarone (1 mM), NDBD (1 mM), and NDEA (1 mM) inhibit EET formation in H9c2 cells inconsistently across the 4 regioisomeric EETs (Figure 8 ). For instance, amiodarone (1 mM) inhibited the formation of 14, 15-EET (15%) and 11, 12-EET (30%) but not 8, 9-EET and 5, 6-EET. Reduction of Protective Effects of 11, 12-EET and 14, 15-EET by 5-HD 11, 12-EET and 14, 15-EET (0.1 mM) prevented Dw m dissipation. The pretreatment of 5-HD (500 mM) significantly abrogated the protective effects of 11, 12-EET ( Figure 10A ) and 14, 15-EET ( Figure 10B ) against Dw m dissipation.
DISCUSSION
In this study, we investigated mitochondrial toxicity induced by dronedarone, amiodarone, NDBD, and NDEA in rat cardiomyocytes and isolated rat heart mitochondria and the subsequent mitigation of the toxicity via enrichment with EETs. We first investigated the potential mitochondrial toxicity of the compounds by measuring cytotoxicity and the reduction of intracellular ATP concurrently in differentiated H9c2 cells. To be classified as a mitochondrial toxin using the Mitochondrial ToxGlo assay, the initiation of mitochondrial damage depicted by the reduction of ATP should occur before cytotoxicity. Alternatively, the trend of increasing cytotoxicity in the background of completely depleted ATP levels is indicative of mitochondrial damage (Kamalian et al., 2015) . Dronedarone, amiodarone, NDBD and NDEA and positive controls rotenone and malonate depleted intracellular ATP prior to the cytotoxicity matching the criteria of mitochondrial toxicity (Figs. 3A-F) .
In healthy, well-coupled mitochondria, seamless ATP production is possible due to a tight control of the Dw m . Conversely, the disruption in Dw m leads to decrease in ATP reserves, cytoplasmic Ca 2þ overload, decrease in NAD þ /NADH ratio and opening of mitochondrial permeability transition pore (MPTP), hallmarks for apoptotic and necrotic cell death pathways (Kroemer et al., 2007) . To further interrogate mitochondrial toxicity, we measured the disruption of Dw m by our test compounds using TMRM dye and found that dronedarone was comparatively more potent in dissipating Dw m in H9c2 cells (Figure 4 ). Our findings suggest that ATP reduction and subsequent H9c2 cell death caused by the compounds are possibly associated with dissipation of Dw m. Investigation into the ETC activity revealed that dronedarone and amiodarone are more potent inhibitors of NADH-dependent (Figs. 5A-D) than succinatedependent ETC activities (Figs. 5E and 5F) indicative of complex I inhibition. Interestingly, all 4 drugs show equipotent uncoupling of ETC at concentrations as low as 0.1 mM (Figure 6 ), suggesting dual roles in impeding oxidative phosphorylation. It is important to point out that the concentrations at which the drugs uncouple the ETC are lower than IC 50 of Dw m dissipation observed in H9c2 cells, corroborating the central role of ETC uncoupling and proton leak leading to dissipation of Dw m . It has been previously shown that dronedarone and amiodarone potently inhibit complex I and uncouple ETC in isolated liver mitochondria in addition to ATP depletion and Dw m dissipation in HepG2 cells (Felser et al., 2013) . Our consistent findings suggest the antiarrhythmic drugs might cause mitochondrial toxicity in both cardiac and hepatic tissues. As dronedarone and amiodarone are highly plasma protein bound drugs (96% and 99%, respectively), the unbound plasma concentrations of dronedarone (0.5-2 mM) and amiodarone (0.2 mM) in rats are relatively low (Jardan and Brocks, 2016; Jardan et al., 2014; Wyss et al., 1990) . On the other hand, the steady state cardiac concentrations of amiodarone (7.04-44.32 mM) and dronedarone (1.89-18.8 mM; considering tissue-to-plasma partition ratio of 9.47; Schmitt, 2008) in rats are significantly higher owing to their high lipophilicity and tissue-plasma partition ratio (Riva et al. (1982) ; Rodrigues et al., 2013 Plomp et al., 1985 . Hence the total cardiac concentrations of these drugs in rat hearts are possibly sufficient to elicit mitochondrial dysfunction. CPT1 is a cardinal enzyme involved in transport of longchain fatty acids via the carnitine shuttling pathway (Supplementary Figure 5) (Kerner and Hoppel, 2000) . Chronic CPT1 inhibition is known to cause hypertrophy-like conditions in mice (Wolkowicz et al., 1999; Cabrero, 2003) . Moreover, cpt1b þ/À mice experience exacerbation of cardiac hypertrophy leading to lipotoxicity and death (Haynie et al., 2014; He et al., 2012) . Similarly, CPT1 inhibition was shown to be the main pathway of mitochondrial toxicity in dronedarone-induced hepatotoxicity in mice (Serviddio et al., 2011; Felser et al., 2014) . In this study, we first determined cpt1a and not cpt1b genes are expressed in H9c2 cells (Supplementary Figure 2) which corroborates previous report (Branco et al., 2015) . We found modest inhibition of CPT1 activity by dronedarone and amiodarone while the metabolites were marginally more potent than their parent compounds ( Figure 7 ). The concentrations of dronedarone and amiodarone were selected based on previous studies where the IC 50 values for cardiac CPT1 inhibition by dronedarone and amiodarone were found to be 40 and 134 mM, respectively (Chong et al., 2014; Kennedy et al., 1996) . Similar low potencies were observed in isolated rat heart mitochondria where the inhibitory concentrations of CPT1 activity are well above the inhibitory concentrations against other biochemical endpoints of mitochondrial toxicity (Supplementary Figure 3) . In summary, inhibition of CPT1 and fatty acid b-oxidation is unlikely an underpinning mechanism of cardiac mitochondrial toxicity associated with the test compounds. We previously reported dronedarone, amiodarone, NDBD and NDEA inhibit cardiac CYP2J2 and perturb the AA metabolic pathway (Karkhanis et al., 2017) . Here, we confirmed the expression of cyp2j3 and ephx2 in the H9c2 cells ( Supplementary  Figure 2) which corroborates previous report (Zordoky and ElKadi, 2007) . Next, we confirmed for the first time that dronedarone inhibits AA regio-epoxygenation potently and consistently in H9c2 cells (Figure 8) . Conversely, the extent of inhibition by amiodarone, NDBD, and NDEA are variable and productdependent. Potent inhibition of AA epoxygenation in H9c2 cells by MS-PPOH, danazol, and sulfaphenazole validated our assay. Collectively, our findings hinted dronedarone might potentially reduce the cardioprotective effects of EETs thus exacerbating cardiac adverse effects.
EETs protect against cell death under stress conditions. For instance, 11, 12-EET was found to increase the expression of mitochondrial and total superoxide dismutases and catalase, and prevent both arsenic trioxide induced apoptosis in HepG2 cells (Liu et al., 2011) and tumor necrosis factor-a injury in H9c2 cells (Zhao et al., 2012) . Similarly, 14, 15-EET mitigated cell death under varied proapoptotic conditions such as tumor necrosis factor-a injury, isoproterenol-induced cardiac hypertrophy and ischemia-reperfusion injury (Geng et al., 2017; Tse et al., 2013; Zhao et al., 2012) . One of important pathways of EET-mediated antiapoptosis is via activation of mitoK ATP channels even at concentrations as low as 10 nM (Lu et al., 2001) . EETs activate of mitoK ATP channels, preserve mitochondrial Dw m and hinder the opening of MPTP in H9c2 cells (Katragadda et al., 2009) . Consistently, EETs protected H9c2 cells from dronedarone, amiodarone, NDBD and NDEA-induced cytotoxicity, reduction of ATP and Dw m dissipation in a concentration-dependent manner ( Figure 9 ). It is important to note that the protective effects of EETs were detectable at 1 nM. Conversely, H9c2 cells pretreated with 5-HD yielded significant reduction in the protective effects of EETs towards the maintenance of Dw m (Figure 10 ). This confirms the EET-induced preservation of Dw m and antiapoptosis are mediated via activation of mitoK ATP channels.
EETs are autocrine and paracrine lipid mediators generated in situ. Out of total EETs generated, 25% are rapidly incorporated into the cellular phospholipids or are bound to fatty acid binding proteins (Kaspera and Totah, 2009; Zhu et al., 1995) . Hence the endogenous unesterified concentration of EETs in the plasma ranges between 1 and 10 nM (Karara et al., 1992) while the tissue levels can increase to micromolar range with activation of phospholipase A 2 . This implies that EETs are likely to protect cardiomyocytes from toxic effects of the test drugs under physiological conditions. Taken together, we postulate that the pre-treatment of H9c2 cells with EETs prior to the treatment with dronedarone, amiodarone, NDBD, or NDEA, possibly maintains Dw m , which in turn prevents ATP loss, mitigates MPTP opening and prevents resultant cell death.
In conclusion, dronedarone, amiodarone, NDBD and NDEA inhibit complexes I and II of the ETC, uncouple ETC, dissipate Dw m , reduce intracellular ATP and cause H9c2 cell death under physiologically relevant conditions, without implication of CPT1 inhibition. These adverse mitochondrial effects are mitigated when H9c2 cells are pretreated with EETs. Notably, dronedarone, unlike amiodarone, inhibits AA-EETs metabolism in H9c2 cells consistently and significantly. Based on our novel findings, we postulate that the clinical cardiac adverse effects associated with dronedarone might in part be a culmination of its direct mitochondrial toxicity and its indirect dysregulation of the AA-EETs metabolic axis.
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